News & Events
10 May 2012 DIABETES AT THE COALFACE
Following on from the success of last year’s event, I am delighted to announce that the Welsh Conference of the Primary Care Diabetes Society will be held again in Cardiff on 10 May this year.
Hosted by Dr Pam Brown and Dr David Millar-Jones, Welsh representatives of the PCDS, this event will provide you with continuing professional development, an opportunity to learn from some leading diabetes experts in Wales and a chance to network with your peers and discuss the key issues that affect you in day-to-day clinical practice.
Through lectures and interactive masterclasses this event will provide practical guidance to healthcare professionals on issues that impact everyday diabetes practice in Wales. Entitled “Diabetes at the Coalface – Management strategies for type 2 diabetes in Wales”, this year’s event covers topics including:
- Diagnosing diabetes and how to screen for it
- Diabetes therapies: out with the old and in with the new?
- Obesity: a Welsh perspective
New resources due to be launched before this year’s conference will also provide you with extended CPD opportunities, such as online post-event education and tools to help you put in place action plans within your practice.
This cost to attend this event this year has been reduced to £75 for PCDS members* and £95 for non-members. However, by booking before 29 February, you can take advantage of the of the early-bird price of £60 and £75 respectively.
For more information or to book on this exciting conference please click here or call the events team on: 0207 627 1510.
We hope that you will be able to join us at this important and influential event.
In this study 34% of the participants had diabetes, Results: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure (NEJM)
Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS
No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study (Takeda)
Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care
The RAMP-DM resulted in greater improvements in HbA1c and reduction in observed and predicted cardiovascular risks at 12 months follow-up, which indicated a risk-stratification multidisciplinary intervention was an effective strategy for managing Chinese people with diabetes in the primary care setting (Cardiovascular Diabetology)
Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study
There are patients for whom glycaemic control worsens and a majority remained above the recommended level, suggesting an unmet need despite the availability of many OAD (BMC Endocrine Disorders)
Postpartum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus
This is the first report that identifies C-peptide and ghrelin as potential biomarkers for the prediction of type 2 diabetes in women with a history of GDM (Journal of Diabetes)